STSijo Joseph Thandapilly

Sijo Joseph Thandapilly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sijo Joseph Thandapilly has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The efficacy of resveratrol in controlling hypertension: study protocol for a randomized, crossover, double-blinded, placebo-controlled trial

    by Ali Movahed, Afshin Ostovar, Daryoush Iranpour, Sijo Joseph Thandapilly, Pema Raj, Xavier Lieben Louis, James Michael Smoliga, Thomas Netticadan

    Hypertension is a global health concern for which novel treatment strategies are necessary. The aim of this study is to evaluate the efficacy of resveratrol (trans-3, 5, 4′-trihydroxystilbene, a polyphenol present in grapes) in controlling blood pressure in participants diagnosed with prehypertension and stage 1 hypertension. In a randomized, crossover, double-blinded, placebo-controlled study, 50 participants with prehypertension (diastolic blood pressure and systolic blood pressure, 80–89 mmHg and 120–139 mmHg, respectively) and 50 participants with stage 1 hypertension (diastolic and systolic, 90–99 mmHg and 140–159 mmHg, respectively) will be assigned to receive resveratrol (99 % pure, from Biotivia Longevity Bioceuticals LLC Company, USA, in 500 mg capsules, twice daily for 4 weeks, orally) or placebo (500 mg neutral microcellulose capsules, twice daily for 4 weeks) in a 2 × 2 crossover design (4 weeks treatment—4 weeks washout—4 weeks treatment). The blood pressure of each participant will be recorded (a mean of two times within a 15-minute interval) every week during the study. The participants in the prehypertensive group will not receive any medication, while those in the stage 1 hypertensive group will continue to receive their routine medications during the study. Blood samples will be taken from all groups and examined for various biochemical parameters. This trial will help to establish whether resveratrol is an effective antihypertensive agent in prehypertensive and stage 1-hypertensive patients. The trial outcome will provide novel insight into the clinical efficacy of resveratrol and provide valuable information for conducting future clinical studies with resveratrol. Iranian Registry of Clinical Trials, IRCT201407078129N7. Registered on 15 August 2014.


  • Effects of Processing, Cultivar, and Environment on the Physicochemical Properties of Oat β‐Glucan

    by Xin Wang, YiFang Chu, Joanne Storsley, Sijo Joseph Thandapilly, Nancy Ames

    Several food regulatory agencies around the world have approved health claims for oat‐derived β‐glucan for cholesterol lowering and glycemic control. The biological efficacy of β‐glucan appears to depend both on daily intake and on physicochemical properties, such as molecular weight and viscosity. The objective of this study was to determine the effects of oat processing, genotype, and growing location on the physicochemical properties of β‐glucan. Five oat genotypes (HiFi, Leggett, CDC Dancer, Marion, and CDC Morrison) grown in two locations (Saskatoon and Kernen) were dehulled (untreated) and processed in a pilot facility through kilning (kilned, not flaked) and subsequent steaming and flaking (kilned, flaked). Untreated groats gave a relatively low Rapid Visco Analyzer (RVA) apparent viscosity (164 cP) and a low extractable β‐glucan molecular weight (332,440) but exhibited high β‐glucan solubility (90.49%). Compared with untreated groats, the kilned (not flaked) samples had significantly increased RVA apparent viscosity (314 cP) and extractable β‐glucan molecular weight (604,710). Additional processing into kilned and flaked products further increased RVA apparent viscosity (931 cP) and β‐glucan molecular weight (1,221,760), but β‐glucan solubility (63.83%) was significantly reduced. Genotype and growing environment also significantly affected β‐glucan viscosity and molecular weight, but no significant interaction effects between processing, genotype, and environment were found. Results indicate that there is potential for processors to improve the physicochemical and nutritional properties of oat end products through processing of specific oat genotypes from selected growing locations.


  • Open Access

    Effect of consuming novel foods consisting high oleic canola oil, barley β-glucan, and DHA on cardiovascular disease risk in humans: the CONFIDENCE (Canola Oil and Fibre with DHA Enhanced) study – protocol for a randomized controlled trial

    by Vanu R. Ramprasath, Sijo J. Thandapilly, Shuo Yang, Anjalika Abraham, Peter J. H. Jones, Nancy Ames

    Metabolic syndrome (MetS) has been identified as a major contributor to the development of cardiovascular disease (CVD). Current recommendations for dietary management of people with MetS involve quantitative and qualitative modifications of food intake, such as high consumption of vegetables, fruits, and whole grain foods. The results from our previous human trials revealed the potential of the dietary components high-oleic acid canola oil (HOCO)-docosahexaenoic acid (DHA) and high molecular weight barley β-glucan individually in managing CVD risk factors. Foods with a combination of HOCO-DHA and barley β-glucan have never been tested for their effects on CVD risk. The objective is to determine the effects of consuming novel foods HOCO-DHA, and barley β-glucan on managing CVD risk factors in people with MetS. We are conducting a randomized, single-blind crossover trial with four treatment phases of 28 days each separated by a 4-week washout interval. Participants (n=35) will be provided with weight-maintaining, healthy balanced diet recommendations according to their energy requirements during the intervention periods. Participants will receive muffins and cookies as treatment foods in a random order and will consume at least one meal per day at the research center under supervision. The four treatments include muffins and cookies consisting of (1) all-purpose flour and HOCO-DHA (50 g/day); (2) barley flour (4.36 g/day of β-glucan) and a blend of sunflower oil, safflower oil, and butter as control oil (50 g/day); (3) barley flour (4.36 g/day of β-glucan) and HOCO-DHA (50 g/day; dosage of DHA would be 3 g/day); and (4) all-purpose flour and control oil (50 g/day). At the beginning and end of each phase, we will evaluate anthropometrics; systolic and diastolic blood pressure; blood lipid profile; low-density lipoprotein subfractions and particle size; 10-year Framingham CVD risk score; inflammatory status; and plasma and red blood cell fatty acid profiles, fecal microbiome, and body composition by dual-energy X-ray absorptiometry. Cholesterol synthesis will also be studied, using a stable isotope approach. The proposed study will lead to innovation of novel food products, which may result in improvement in the overall cardiovascular health of humans. Clinical trials.gov identifier: NCT02091583 . Date of registration: 12 March 2014.


  • Open Access

    Why a new journal, Diabesity- editorial perspectives

    by Sijo Joseph Thandapilly

    I am very pleased to write an inaugural editorial for the new journal, Diabesity as the editor-in-charge. Diabesity is a unique peer-reviewed open access interdisciplinary journal dedicated to publishing high-quality articles in the areas of physiology, pathology and therapeutic aspects of diabetes, obesity and their complications. Diabesity focuses on clinical and experimental pharmacology and therapeutics in any aspect of these metabolic ailments in various experimental and clinical settings. Current therapeutic agents for obesity and diabetes are inadequate as the number of cases is on the rise. Along with public health strategies, development of alternative therapeutic agents is anticipated. Therefore, extensive research is being conducted in this field and is drawing intense attention from researchers, practitioners and the general public. Here arises the significance of a journal like Diabesity which can serve as a platform for knowledge sharing and the promotion and dissemination of new scientific advancements to a wide spectrum of readers.